Some semaglutide groups lost weight and had fewer major illnesses

The main semaglutide benefits concern weight and certain illnesses

Did semaglutide do more than lower weight? Yes, heart and kidney illness also decreased in certain groups. Your health needs may differ from the needs tested. Other uses and possible harms aren't settled by those results.

After eating, your gut releases GLP-1, which semaglutide copies. GLP-1 helps the pancreas, behind your stomach, release insulin as sugar rises. Insulin lets your cells draw sugar out of the bloodstream. Semaglutide also limits over-release of another hormone, which pushes sugar upward.

Hunger can ease, and the stomach releases food more slowly. Trials counted fewer strokes, heart attacks or fatal heart problems together. Major kidney problems or deaths fell in people living with type 2 diabetes and long-lasting kidney disease ^[2][3][4]. Researchers found the fall by comparing treatment groups.

Fat isn't the only part you can lose, muscle can decrease too. Your scale can't measure how strong your muscles remain. Feeling sick and gallbladder disease are known concerns ^[5]. Stones can form in your gallbladder, which holds fluid used in digestion.

The medicine lasts longer than the hormone made in your gut

Ozempic and Wegovy both contain semaglutide, the drug studied here. Semaglutide acts like GLP-1, which your gut releases after meals. That hormone affects how hungry you feel and helps control blood sugar. Naming a medicine doesn't mean the guide endorses that product.

Your body breaks down its own gut hormone quite fast. Semaglutide was changed to resist that breakdown for longer. A protein in blood also holds the drug there longer. Those changes help semaglutide outlast your body's own GLP-1.

Early studies checked sugar in blood and people's weight. Later trials counted heart disease and major kidney problems too. That gives you findings about illness alongside findings about weight. The people tested still limit what each finding can tell you.

People already facing heart disease don't represent everyone's health. Lasting kidney disease also has different forms and levels of harm. Approved semaglutide medicines have different allowed uses on their labels. The name alone doesn't tell you whether an allowed use fits.

Eating less explains the main weight loss effect

Several body parts respond when semaglutide acts like GLP-1. As blood sugar increases, the pancreas sends more insulin into blood. Your cells use insulin to draw sugar from the bloodstream. Semaglutide also limits excess release of the hormone raising sugar.

With semaglutide, food moves onward from your stomach more slowly. Changed brain messages ease your hunger and bring fullness sooner. A smaller meal can leave you feeling satisfied sooner. Food preferences can change too, and people often eat less.

Less food eaten accounts for most of the measured weight loss. Burning much more energy isn't the main reason weight falls. Your strength remains a separate question from your food intake. Your lost weight can't establish how well muscles still work.

The slowing of stomach emptying can also bring on nausea. Bloating, vomiting, constipation or diarrhea can happen during treatment. Reflux means stomach acid moves back toward your throat. That acid can cause heartburn, so the slower stomach has drawbacks.

Weight and illness trials gave separate answers

Twenty twenty-one: STEP 1 tested adults without diabetes carrying excess weight. Obesity means enough excess body fat to count as a medical illness. At 68 weeks, average changes were −14.9% with semaglutide and −2.4% with placebo, made without any active drug ^[4]. Both figures describe losses, with greater loss from semaglutide.

Twenty twenty-three: SELECT tested 17,604 adults carrying extra weight while already facing heart disease. They didn't have diabetes when the trial began. Semaglutide reduced the combined count of strokes, heart attacks and fatal heart illness ^[3]. Your own chances of those problems can't be predicted here.

Twenty twenty-four: FLOW included 3,533 people with type 2 diabetes and lasting kidney disease. Researchers counted failing kidneys, large drops in kidney function, and certain deaths. The semaglutide group had fewer than the group receiving placebo ^[2]. That finding doesn't cover every kind of kidney illness.

Twenty twenty-five: 751 adults carrying extra weight received semaglutide or tirzepatide for comparison. Average changes after 72 weeks were −13.7% with semaglutide and −20.2% with tirzepatide ^[1]. Both groups lost weight, and tirzepatide produced more loss. Neither tesamorelin nor MOTS-c was tested in that comparison.

Personal reports cannot give you a reliable harm rate

People describe what happened while trying semaglutide for research themselves. These are personal experiences, rather than findings from a trial comparing treatment groups. The accounts don't reliably distinguish prescribed use from people trying semaglutide themselves.

People describe weight loss, reduced cravings and fullness coming sooner. Reports also describe tiredness, sickness, bowel changes, reflux and unpleasant burping. A personal account doesn't establish what caused each change. You can't use those accounts to count how often harm occurs.

Twenty twenty-one: a safety review described usually temporary digestive troubles ^[5]. Most troubles weren't severe, usually mild or moderate. Roughly one-third felt sick, so nausea affected many patients. Gallbladder disease, including stones, also became more likely during treatment.

The same review couldn't settle rare cancer concerns ^[5]. Too few cancers occurred to establish or rule out a link. The concerns involved your pancreas and your neck's thyroid gland. The thyroid helps control energy use, while your pancreas helps digestion and sugar control.

Rapid weight loss can include loss of muscle weight. That concern remains despite the benefits for heart and kidney illness. Your eating, strength and walking need checks of their own. Your lower weight doesn't settle all those separate questions.

Heart trials did not settle how well muscles worked

The human trials of semaglutide cover the broadest range here. Researchers checked weight, serious heart illness and major kidney problems ^[2][3][4]. The findings concern the particular patients those trials enrolled. Your walking and strength weren't settled by those illness counts.

Weighing your body resembles weighing a sack without opening it. You know the total, without seeing what each part weighs. Muscle, fat and water can change by different amounts. Your grip, walking and muscle size need their own checks.

Tesamorelin trials chiefly measured where fat and other weight changed. MOTS-c tests mostly checked movement in mice or cells using sugar. Those studies can't pick the right medicine for your health. Their approved uses and the people tested also differ.